Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma
Written by
Cancer Network
Published
0
comments
0
min
A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.